Apogee Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Apogee Therapeutics, Inc. (APGE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $38.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-02
- Apogee Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $10.20M, a 137.21% increase year-over-year.
- Apogee Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $10.50M, a 105.88% increase year-over-year.
- Apogee Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $10.90M, a 275.86% increase year-over-year.
- Apogee Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-03-31 was $7.40M, a 311.11% increase year-over-year.
- Apogee Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $38.50M, a 173.05% increase from fiscal 2024.
- Apogee Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $14.10M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $20.70M derived: sum of 2 quarters · filed 2026-03-02 | $31.60M derived: sum of 3 quarters · filed 2026-03-02 | $38.50M 10-K · filed 2026-03-02 |
| 2025-09-30 | $10.50M 10-Q · filed 2025-11-10 | $21.40M derived: sum of 2 quarters · filed 2025-11-10 | $28.30M 10-Q · filed 2025-11-10 | $33.10M derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | $10.90M 10-Q · filed 2025-08-11 | $18.20M 10-Q · filed 2025-08-11 | $22.60M derived: sum of 3 quarters · filed 2025-08-11 | $27.70M derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | $7.40M 10-Q · filed 2025-05-12 | $11.70M derived: sum of 2 quarters · filed 2025-05-12 | $16.80M derived: sum of 3 quarters · filed 2025-05-12 | $19.70M derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $9.40M derived: sum of 2 quarters · filed 2025-03-03 | $12.30M derived: sum of 3 quarters · filed 2025-03-03 | $14.10M 10-K · filed 2025-03-03 |
| 2024-09-30 | $5.10M 10-Q · filed 2024-11-12 | $8.00M derived: sum of 2 quarters · filed 2024-11-12 | $9.80M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $2.90M 10-Q · filed 2024-08-12 | $4.70M 10-Q · filed 2024-08-12 | ||
| 2024-03-31 | $1.80M derived: 10-K 12 month − 3 quarters · filed 2025-03-03 |